A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
Latest Information Update: 31 Jul 2024
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 31 Jul 2024 According to a Daiichi Sankyo Company media release, in June 2024, the application was approved in China for the use of mirogabalin (DS-5565: (alpha 2 delta) ligand, brand name in Japan: Tarlige) for the treatment of diabetic peripheral neuropathic pain.
- 28 Feb 2022 Status changed from active, no longer recruiting to completed.
- 04 Oct 2021 Status changed from recruiting to active, no longer recruiting.